Article
Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis.
Cancer chemotherapy and pharmacology - 1 Aug 2010
Bouchahda Mohamed, Karaboué Abdoulaye, Saffroy Raphaël, Innominato Pasquale, Gorden Lee, Guettier Catherine, Adam René, Lévi Francis
Abstract excerpt
PURPOSE: Documentation of a wild-type (wt) KRAS gene in tumor has become mandatory for the prescription of anti-EGFR monoclonal antibodies in patients with colorectal cancer (CRC). Acquired KRAS mutations have seldom been reported in metastases from wt KRAS primary CRC. We report the first case of multiple KRAS mutations acquired during the metastatic phase of CRC, and retrospectively reviewed all patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.